Sherlock Biosciences

Sherlock Biosciences

  • Founded: 2018
  • Location: Watertown, MA
  • Employee range: 11 - 50
  • Funding: $80M B Mar 2022; $7.5M grant May 2020; $31M A Mar 2019
  • Investors: Northpond Ventures, Baidu Ventures, Open Philanthropy Project

job board

Short description:

Molecular Diagnostics

Drug notes:

Contact us to add description:

Long description:

Sherlock Biosciences is using CRISPR technology to revolutionize diagnostics for DNA and RNA detection. Sherlock’s diagnostic tests are rapid, accurate, affordable and developed to be used at any time and location from saliva, urine, or blood. The company has two main diagnostic platforms: SHERLOCK and INSPECTR. SHERLOCK uses CRISPR technology and ‘smart amplicon detection’ to detect a specific nucleic acid signature in any organism or pathogen. A SARS-Cov-2 SHERLOCK kit has recently been FDA approved for clinical use. INSPECTR consists of dried synthetic gene networks that produce a reporter protein via cell-free transcription/translation upon target presence. Sherlock aims to decentralize testing anywhere to personalize healthcare and impact global health.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy